Scinai Immunotherapeutics Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $1.7M
- Price
- $1.26
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.16%
- Volume
- 4.3K
About
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
Quick stats
Shares outstanding1.4M
Computed float—
Float / sharesUnknown
Cash runway (months)2.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001611747
Websitehttps://www.scinai.com
AI Summary
AI-generated1/9
minorbullishregulatory
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
Scinai Immunotherapeutics (Nasdaq: SCNI) received written notification from Nasdaq Listing Qualifications confirming it has regained compliance with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), and the matter is now closed.
Nasdaq staff had notified the company on March 12, 2026 that its ADSs failed to maintain a $1.00 minimum bid over 30 consecutive business days. A September 18, 2026 compliance letter stated the closing bid was at $1.00 per share or greater for 19 consecutive business days from August 21 through September 17, 2026.
CEO Amir Reichman said resolving the matter lets the company focus on commercial execution at its CDMO, Scinai Biopharma Services, and disciplined advancement of its NanoAb programs.
Red flags
- ADSs traded below $1.00 long enough to trigger a March 12, 2026 Nasdaq deficiency notice; renewed breach remains a live risk if the bid slips again
- Forward-looking statements flag dependence on securing sufficient financing or non-dilutive funding on satisfactory terms or at all